Teva Pharmaceutical Industries Ltd., declared today that the U.S. Sustenance and Drug Administration (FDA) has acknowledged for survey the Biologics License Application (BLA) for reslizumab, the organization’s investigational acculturated monoclonal immune response (mAb) which targets interleukin-5 (IL-5), for the treatment of insufficiently controlled asthma in grown-up and immature patients with hoisted blood eosinophils, in spite of a breathed in corticosteroid (ICS)-based regimen.